Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Labuxtinib SCHEMBL24508232 | 1.00 | KIT (1.00) | KIT | |
| Labuxtinib SCHEMBL14738734 | 1.00 | KIT (1.00) | KIT | |
| Labuxtinib SCHEMBL14751407 | 1.00 | KIT (1.00) | KIT | |
| Labuxtinib SCHEMBL14739429 | 1.00 | KIT (1.00) | KIT | |
| Labuxtinib SCHEMBL20844934 | 1.00 | KIT (1.00) | KIT | |
| Labuxtinib SCHEMBL29562904 | 0.99 | KIT (0.98) | KIT | |
| Labuxtinib SCHEMBL29441810 | 0.95 | KIT (0.91) | KIT | |
| SCHEMBL14738439 | 0.92 | KIT (1.00) | KIT | |
| SCHEMBL27336503 | 0.91 | KIT (0.84) | KIT | |
| SCHEMBL14738475 | 0.91 | KIT (1.00) | KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4247368-A1 | PHARMACEUTICAL COMPOSITIONS OF A SELECTIVE C-KIT KINASE INHIBITOR AND METHODS FOR MAKING AND USING SAME | Third Harmonic Bio, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| US-11744823-B2 | Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same | THIRD HARMONIC BIO, INC. (US) | 2023-09-05 | — | — | US | claimed |
| WO-2022182982-A1 | METHODS FOR TREATING C-KIT KINASE MEDIATED DISEASES AND DISORDERS USING A SELECTIVE C-KIT KINASE INHIBITOR | THIRD HARMONIC BIO, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| US-20220194936-A1 | CRYSTALLINE FORMS OF N-(5-(5-((1R,2S)-2-FLUOROCYCLOPROPYL)-1,2,4-OXADIAZOL-3-YL)-2-METHYLPHENYL)IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE | NOVARTIS AG (CH) | 2022-06-23 | — | — | US | claimed |
| US-20220184045-A1 | PHARMACEUTICAL COMPOSITIONS OF A SELECTIVE C-KIT KINASE INHIBITOR AND METHODS FOR MAKING AND USING SAME | Calixis Inc. | 2022-06-16 | — | — | US | claimed |
| US-20220175740-A1 | PHARMACEUTICAL COMPOSITIONS OF A SELECTIVE C-KIT KINASE INHIBITOR AND METHODS FOR MAKING AND USING SAME | NOVARTIS AG (CH) | 2022-06-09 | — | — | US | claimed |
| WO-2022106615-A1 | PHARMACEUTICAL COMPOSITIONS OF A SELECTIVE C-KIT KINASE INHIBITOR AND METHODS FOR MAKING AND USING SAME | NOVARTIS AG (CH) | 2022-05-27 | — | — | WO | claimed |
| WO-2022109595-A1 | PHARMACEUTICAL COMPOSITIONS OF A SELECTIVE C-KIT KINASE INHIBITOR AND METHODS FOR MAKING AND USING SAME | THIRD HARMONIC BIO, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| EP-3969453-A1 | CRYSTALLINE FORMS OF N- (5- (5- ( (1R, 2S) -2-FLUOROCYCLOPROPYL) -1, 2, 4-OXADIAZOL-3-YL) -2-METHYLPHENYL) IMIDAZO [1, 2-A] PYRIDINE-3-CARBOXAMIDE | Novartis AG (CH) | 2022-03-23 | — | — | EP | claimed |
| CN-114096538-A | Crystalline forms of N- (5- (5- ((1R,2S) -2-fluorocyclopropyl) -1,2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1,2-A ] pyridine-3-carboxamide | 诺华股份有限公司 | 2022-02-25 | — | — | CN | claimed |
| EP-2751102-B1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-03-27 | — | — | EP | claimed |
| US-9199981-B2 | Compounds and compositions as C-kit kinase inhibitors | NOVARTIS AG (CH) | 2015-12-01 | — | — | US | claimed |
| EP-2751102-A1 | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-07-09 | — | — | EP | claimed |
| WO-2013033070-A1 | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | claimed |
| US-20130059846-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | US | claimed |
| EP-4630423-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | Third Harmonic Bio, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024123966-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | THIRD HARMONIC BIO, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2013033070-A1 | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033070-A1 | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059846-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184045-A1 | PHARMACEUTICAL COMPOSITIONS OF A SELECTIVE C-KIT KINASE INHIBITOR AND METHODS FOR MAKING AND USING SAME | KIT, PHKG1, PHKG2 | KIT 1/4885 |
| US-20220175740-A1 | PHARMACEUTICAL COMPOSITIONS OF A SELECTIVE C-KIT KINASE INHIBITOR AND METHODS FOR MAKING AND USING SAME | KIT, PHKG1, PHKG2 | KIT 1/4885 |
| US-20130059846-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | KIT 1/4885 |
| US-20220194936-A1 | CRYSTALLINE FORMS OF N-(5-(5-((1R,2S)-2-FLUOROCYCLOPROPYL)-1,2,4-OXADIAZOL-3-YL)-2-METHYLPHENYL)IMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE | FH, FFAR2, FBP1 | KIT 37/4885 |
| US-11744823-B2 | Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same | KIT, PHKG1, PHKG2 | KIT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.